RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC
Objective: Immune thrombocytopenia (ITP) is an acquired immune-mediated disease that lacks an underlying etiology. Steroids are the main first-line treatment of ITP, while the second-line treatment consists primarily of splenectomy and rituximab. This study aimed to assess and compare the response...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-02-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://www.mjhid.org/mjhid/article/view/5562 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568880629809152 |
|---|---|
| author | Rawanda Shamoon Ahmed Khudair Yassin Sarah Laith Alnuaimi |
| author_facet | Rawanda Shamoon Ahmed Khudair Yassin Sarah Laith Alnuaimi |
| author_sort | Rawanda Shamoon |
| collection | DOAJ |
| description |
Objective: Immune thrombocytopenia (ITP) is an acquired immune-mediated disease that lacks an underlying etiology. Steroids are the main first-line treatment of ITP, while the second-line treatment consists primarily of splenectomy and rituximab. This study aimed to assess and compare the response to rituximab and splenectomy.
Methods: This retrospective comparative study reviewed ITP patients treated at a single private hematology clinic from 2007 to 2019. Seventy-four ITP patients were recruited, 27 were on rituximab, and 47 had undergone splenectomy. The initial platelet counts and bleeding symptoms were recorded, and initial and long-term responses to treatment were evaluated based on the American Society of Hematology guidelines.
Results: The mean age of the patients was 42.1 years with a male-to-female ratio of 1:1.8. The initial mean platelet count was comparable between the rituximab and splenectomy groups (p = 0.749). The initial complete response (CR) differed significantly between the rituximab and splenectomy groups (44.4% versus 83%, p = 0.002). The five-year response rate was significantly higher in the splenectomy than in the rituximab group (74% versus 52%, log-rank 0.038). Splenectomy was the only significant predictive factor for long-term response (OR = 0.193, p = 0.006).
Conclusion: The overall response revealed that splenectomy appeared superior to rituximab as a second-line treatment of ITP. Splenectomy was the only positive prognostic indicator of sustained response.
|
| format | Article |
| id | doaj-art-e9b1756da36443439de5a34f1a0f4c5e |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-e9b1756da36443439de5a34f1a0f4c5e2025-02-03T00:08:31ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062024-02-0116110.4084/MJHID.2024.019RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINICRawanda Shamoon0Ahmed Khudair Yassin1Sarah Laith Alnuaimi2Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Iraq. Department of Internal Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq. Department of Clinical Hematology, Nanakali Hospital of Blood Diseases and Cancer, Erbil, IraqDepartment of Hematology, Nanakali Hospital of Blood Diseases and Cancer, Erbil, Iraq Objective: Immune thrombocytopenia (ITP) is an acquired immune-mediated disease that lacks an underlying etiology. Steroids are the main first-line treatment of ITP, while the second-line treatment consists primarily of splenectomy and rituximab. This study aimed to assess and compare the response to rituximab and splenectomy. Methods: This retrospective comparative study reviewed ITP patients treated at a single private hematology clinic from 2007 to 2019. Seventy-four ITP patients were recruited, 27 were on rituximab, and 47 had undergone splenectomy. The initial platelet counts and bleeding symptoms were recorded, and initial and long-term responses to treatment were evaluated based on the American Society of Hematology guidelines. Results: The mean age of the patients was 42.1 years with a male-to-female ratio of 1:1.8. The initial mean platelet count was comparable between the rituximab and splenectomy groups (p = 0.749). The initial complete response (CR) differed significantly between the rituximab and splenectomy groups (44.4% versus 83%, p = 0.002). The five-year response rate was significantly higher in the splenectomy than in the rituximab group (74% versus 52%, log-rank 0.038). Splenectomy was the only significant predictive factor for long-term response (OR = 0.193, p = 0.006). Conclusion: The overall response revealed that splenectomy appeared superior to rituximab as a second-line treatment of ITP. Splenectomy was the only positive prognostic indicator of sustained response. https://www.mjhid.org/mjhid/article/view/5562ITPrituximabsplenectomycomplete responsesecond-line therapy |
| spellingShingle | Rawanda Shamoon Ahmed Khudair Yassin Sarah Laith Alnuaimi RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC Mediterranean Journal of Hematology and Infectious Diseases ITP rituximab splenectomy complete response second-line therapy |
| title | RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC |
| title_full | RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC |
| title_fullStr | RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC |
| title_full_unstemmed | RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC |
| title_short | RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC |
| title_sort | rituximab versus splenectomy in chronic primary itp experience of a single hematology clinic |
| topic | ITP rituximab splenectomy complete response second-line therapy |
| url | https://www.mjhid.org/mjhid/article/view/5562 |
| work_keys_str_mv | AT rawandashamoon rituximabversussplenectomyinchronicprimaryitpexperienceofasinglehematologyclinic AT ahmedkhudairyassin rituximabversussplenectomyinchronicprimaryitpexperienceofasinglehematologyclinic AT sarahlaithalnuaimi rituximabversussplenectomyinchronicprimaryitpexperienceofasinglehematologyclinic |